In-Depth Expertise in Extracellular Bioscaffolds and Matrices

We apply AccuraMatrix 3D cell culture system to help customers produce their target cells of interest in large scale.

An innovative biomedical engineering platform

Acrogenic Inc. is a biomedical engineering company developing a portfolio of innovative biomaterials and cutting-edge biomedical techniques targeting significant unmet medical needs in therapeutic cells, tissue engineering scaffolds, and novel copolymer drugs.

We also provide unique both in vitro and in vivo models including various 3-D cultured human primary cancer cells organoids, multiple 3-D cultured human normal primary cells organoids, in vitro cultured tissue granules, and a novel system for efficiently developing xenograft tumors for academic researches, pharmaceutical preclinical studies, and a robust anticancer drug screening system.

Acrogenic has in-depth expertise in extracellular bioscaffolds and matrices. Acrogenic provides a series of cutting-edge products for primary cultures, 3D cell culture, organoids development, and high-throughput drug evaluation. These products offer accurate, efficient, economic, and powerful tools for both biomedical research and pharmaceutical industry.

Core Member

Dazhi Yang , Founder

Ph.D. in Cell Development from the Biology Department of Howard University, Postdoctoral Fellow at the National Cancer Institute (NCI) l
Research Scholar at the National Cancer Institute, appointed as a Senior Researcher and Ph.D. Supervisor at the Center for Research on Science and Technology in the United States (CREST).

Laiqiang Ying , CTO

MaPh.D. in Organic Chemistry from the University of California, over 18 years of experience in organic and biochemistry and life sciences, with nearly a decade of research and development experience at Thermo Fisher Scientific in the United States.
Published 9 articles in professional journals, holds 14 U.S. patents.

Dan Ni, CEO

Ph.D. in Physiology from the University of Kentucky, Postdoctoral Research Fellow at the University of Southern California.
Nearly 20 years of experience in biopharmaceutical research and development, business development, and investment.

Hongyi Li , COO

Bachelor of Clinical Medicine from Capital Medical University.Master of Law from Renmin University of China.
Attending Physician in Clinical Medicine at Huaxin Hospital affiliated with Tsinghua University.

Expert Consultant

Member of the National Academy of Engineering of the United States

Dr.James W.Mitchell

Vice President, Materials Processing Research, Bell Labs.
Director of Centers of Research Excellence in Science and Technology. Institute, appointed as a Senior Researcher and Ph.D. Supervisor at the Center for Research on Science and Technology in the United States (CREST).